Skip to main
LNTH

Lantheus Holdings (LNTH) Stock Forecast & Price Target

Lantheus Holdings (LNTH) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 43%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Lantheus Holdings is poised for strong growth in the coming years, with a diversified portfolio of diagnostic and radiotherapeutic products that are addressing unmet needs in both cardiology and oncology. The recent 1Q26 earnings beat demonstrates continued momentum in key products such as Pylarify, DEFINITY, and Neuraceq, while management's conservative approach to guidance and plans to find a successor for the CEO role instills further confidence in the company's future performance. With a strategic focus on expanding its market presence and partnerships, Lantheus Holdings is well-positioned to continue delivering strong revenue and EPS growth in the years ahead.

Bears say

Lantheus Holdings is facing significant challenges as a radiopharmaceutical-focused company, with a lack of contribution from new therapeutic and diagnostic opportunities and a projected flat gross profit for the next year. With a relatively low multiple of 20x, it may be perceived as inexpensive compared to similar-sized, high-growth peers, but its performance and future outlook appear to be lagging behind the industry. The increase in price target to $115 is based on a better visibility to a potential acceleration in 2027, but with the stock currently trading at 17.5x P/E, it may still struggle to close the gap with its peers.

Lantheus Holdings (LNTH) has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 43% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lantheus Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lantheus Holdings (LNTH) Forecast

Analysts have given Lantheus Holdings (LNTH) a Buy based on their latest research and market trends.

According to 7 analysts, Lantheus Holdings (LNTH) has a Buy consensus rating as of Jun 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $94.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $94.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lantheus Holdings (LNTH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.